Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2021:263:185-226.
doi: 10.1007/164_2019_326.

Gastrointestinal Uses of Botulinum Toxin

Affiliations
Randomized Controlled Trial

Gastrointestinal Uses of Botulinum Toxin

Maria Cariati et al. Handb Exp Pharmacol. 2021.

Abstract

Botulinum toxin (BT), one of the most powerful inhibitors that prevents the release of acetylcholine from nerve endings, represents an alternative therapeutic approach for "spastic" disorders of the gastrointestinal tract such as achalasia, gastroparesis, sphincter of Oddi dysfunction, chronic anal fissures, and pelvic floor dyssynergia.BT has proven to be safe and this allows it to be a valid alternative in patients at high risk of invasive procedures but long-term efficacy in many disorders has not been observed, primarily due to its relatively short duration of action. Administration of BT has a low rate of adverse reactions and complications. However, not all patients respond to BT therapy, and large randomized controlled trials are lacking for many conditions commonly treated with BT.The local injection of BT in some conditions becomes a useful tool to decide to switch to more invasive therapies. Since 1980, the toxin has rapidly transformed from lethal poison to a safe therapeutic agent, with a significant impact on the quality of life.

Keywords: Achalasia; Autonomic nervous system diseases; Biliary diseases; Botulinum toxin; Cholinergic nerve ending; Enteric nervous system; Esophageal diseases; Fissures; Gastric emptying; Hirschsprung; Motility; Neuromuscular agents; Obesity; Spasm; Therapeutic agents.

PubMed Disclaimer

References

    1. Achem SR, Gerson LB (2013) Distal esophageal spasm: an update. Curr Gastroenterol Rep 15:325 - PubMed - DOI
    1. Ahmadi J, Azary S, Ashjaei B, Paragomi P, Khalifeh-Soltani A (2013) Intrasphincteric botulinum toxin injection in treatment of chronic idiopathic constipation in children. Iran J Pediatr 23:574–578 - PubMed - PMC
    1. Akaike N, Shin MC, Wakita M, Torii Y, Harakawa T, Ginnaga A, Kato K, Kaji R, Kozaki S (2013) Transsynaptic inhibition of spinal transmission by A2 botulinum toxin. J Physiol 591:1031–1043 - PubMed - DOI - PMC
    1. Albanese A, Maria G, Bentivoglio AR, Brisinda G, Cassetta E, Tonali P (1997) Severe constipation in Parkinson’s disease relieved by botulinum toxin. Mov Disord 12:764–766 - PubMed - DOI
    1. Albanese A, Brisinda G, Mathias CJ (2000) The autonomic nervous system and gastrointestinal disorders. In: Appenzeller O, Vinken PJ, Bruyn GW (eds) Handbook of clinical neurology, vol 75. Elsevier, Amsterdam, pp 613–663

Publication types

Substances

LinkOut - more resources